公开(公告)号：US20150175572A1

公开(公告)日：2015-06-25

申请号：US14642274

申请日：2015-03-09

Applicant: PFIZER INC.

Inventor： Martin Paul EDWARDS ,  Robert Arnold KUMPF ,  Pei-Pei KUNG ,  Indrawan James MCALPINE ,  Sacha NINKOVIC ,  Eugene Yuanjin RUI ,  Scott Channing SUTTON ,  John Howard TATLOCK ,  Martin James WYTHES ,  Luke Raymond ZEHNDER

IPC: C07D401/06 ,  C07D471/04 ,  C07D405/14 ,  C07D401/14 ,  C07D413/14

CPC classification number: C07D401/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract translation: 本发明涉及通式（I）的化合物，其中R1，R2，U，V，L，M，R5，m，X，Y和Z如本文所定义，及其药学上可接受的盐， 这些化合物和盐，以及使用这些化合物，盐和组合物用于治疗异常细胞生长（包括癌症）的方法。

公开(公告)号：US20170152239A1

公开(公告)日：2017-06-01

申请号：US15425732

申请日：2017-02-06

Applicant: PFIZER INC.

Inventor： Martin Paul EDWARDS ,  Robert Arnold KUMPF ,  Pei-Pei KUNG ,  Indrawan James MCALPINE ,  Eugene Yuanjin RUI ,  Scott Channing SUTTON ,  John Howard TATLOCK ,  Martin James WYTHES

IPC: C07D401/14 ,  C07D487/08 ,  C07D409/14 ,  C07D413/14 ,  C07D491/08 ,  C07D213/64 ,  C07D401/12 ,  C07D405/14

CPC classification number: C07D401/14 ,  C07D213/64 ,  C07D401/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/14 ,  C07D413/14 ,  C07D487/08 ,  C07D491/08

Abstract: This invention relates to compounds of general formula in which R1, R2, R6, U, V, W, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and salts, and to methods of using such compounds, salts and compositions.

公开(公告)号：US20180148441A1

公开(公告)日：2018-05-31

申请号：US15826027

申请日：2017-11-29

Applicant: PFIZER INC.

Inventor： Aaron Craig BURNS ,  Michael Raymond COLLINS ,  Samantha Elizabeth GREASLEY ,  Robert Louis Hoffman ,  Peter Qinhua HUANG ,  Robert Steven Kania ,  Pei-Pei KUNG ,  Maria Angelica LINTON ,  Lakshmi Sourirajan NARASIMHAN ,  Paul Francis RICHARDSON ,  Daniel Tyler RICHTER ,  Graham SMITH

IPC: C07D417/14 ,  C07D417/08 ,  C07D277/46 ,  A61K45/06 ,  A61K31/427 ,  A61K31/501 ,  A61K31/444 ,  A61K31/4439 ,  C07D401/14 ,  A61K31/506

CPC classification number: C07D417/14 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07D277/46 ,  C07D401/14 ,  C07D417/08

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

公开(公告)号：US20170233368A1

公开(公告)日：2017-08-17

申请号：US15585880

申请日：2017-05-03

Applicant: Pfizer Inc.

Inventor： Martin Paul EDWARDS ,  Robert Arnold KUMPF ,  Pei-Pei KUNG ,  lndrawan James MCALPINE ,  Sacha NINKOVIC ,  Eugene Yuanjin RUI ,  Scott Channing SUTTON ,  John Howard TATLOCK ,  Martin James WYTHES ,  Luke Raymond ZEHNDER

IPC: C07D401/06 ,  C07D487/04 ,  C07D405/14 ,  C07D471/04 ,  C07D401/14 ,  C07D413/14

CPC classification number: C07D401/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20250049802A1

公开(公告)日：2025-02-13

申请号：US18719456

申请日：2022-12-12

Applicant: Pfizer Inc.

Inventor： Stephen George DANN ,  Koleen Jill EISELE ,  Conglin FAN ,  Manfred KRAUS ,  Pei-Pei KUNG ,  Shikhar SHARMA ,  Hui WANG

IPC: A61K31/519 ,  A61K31/444 ,  A61K31/567 ,  A61P35/00

Abstract: The present disclosure relates to the treatment of cancer and/or cancer-associated disease. Certain aspects relate to the treatment of an individual having cancer or cancer-associated disease by administering to the individual a combination therapy of a first therapeutic agent that is an EZH2 inhibitor, a second therapeutic agent that is a CDK inhibitor, and a third therapeutic agent that is a selective estrogen receptor degrader.

公开(公告)号：US20170050958A1

公开(公告)日：2017-02-23

申请号：US15306979

申请日：2015-04-17

Applicant: PFIZER INC.

Inventor： Aaron Craig BURNS ,  Michael Raymond COLLINS ,  Samantha Elizabeth GREASLEY ,  Robert Louis Hoffman ,  Peter Qinhua HUANG ,  Robert Steven Kania ,  Pei-Pei KUNG ,  Maria Angelica LINTON ,  Lakshmi Sourirajan NARASIMHAN ,  Paul Francis RICHARDSON ,  Daniel Tyler RICHTER ,  Graham SMITH

IPC: C07D417/14 ,  A61K45/06 ,  A61K31/501 ,  C07D401/14 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/444 ,  C07D277/46

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，其中A，L，D，R 1 -R 15，w，x，y和z在本文中定义。 在哺乳动物中可用于治疗异常细胞生长例如癌症的新型环烷基连接的二杂环衍生物。 本发明还涉及含有该化合物的药物组合物以及使用该化合物和组合物治疗哺乳动物异常细胞生长的方法。

公开(公告)号：US20140179667A1

公开(公告)日：2014-06-26

申请号：US14132567

申请日：2013-12-18

Applicant: PFIZER INC.

Inventor： Martin Paul EDWARDS ,  Robert Arnold KUMPF ,  Pei-Pei KUNG ,  Indrawan James MCAPLINE ,  Sacha NINKOVIC ,  Eugene Yuanjin RUI ,  Scott Channing SUTTON ,  John Howard TATLOCK ,  Martin James WYTHES ,  Luke Raymond Zehnder

IPC: C07D401/06 ,  C07D487/04 ,  C07D401/14 ,  C07D471/04 ,  C07D405/14 ,  C07D413/14

CPC classification number: C07D401/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract translation: 本发明涉及其中R1，R2，U，V，L，M，R5，m，X，Y和Z如本文所定义的通式（I）化合物及其药学上可接受的盐， 这些化合物和盐，以及使用这些化合物，盐和组合物来治疗异常细胞生长（包括癌症）的方法。